AU Patent

AU2023203501A1 — PSMA binding dual mode radiotracer and -therapeutics

Assigned to Technische Universitaet Muenchen · Expires 2023-07-06 · 3y expired

What this patent protects

The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F. 0 0 (S) H H N(S)N HO H H H 0 N NR ()H H (S) O H 0 0' N A4K- HO MV

USPTO Abstract

The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F. 0 0 (S) H H N(S)N HO H H H 0 N NR ()H H (S) O H 0 0' N A4K- HO MV

Drugs covered by this patent

Patent Metadata

Patent number
AU2023203501A1
Jurisdiction
AU
Classification
—
Expires
2023-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Technische Universitaet Muenchen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.